Current and historical daily PE Ratio for Vicore Pharma Holding AB (
OSTO:VICO
) from 2015 to Apr 16 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Vicore Pharma Holding AB stock (OSTO:VICO) PE ratio as of Apr 16 2024 is 0.
More Details
Vicore Pharma Holding AB (OSTO:VICO) PE Ratio (TTM) Chart
Vicore Pharma Holding AB (OSTO:VICO) PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Total 1227
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Vicore Pharma Holding AB PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
| 2024-03-11 | At Loss | 2024-01-08 | At Loss |
| 2024-03-08 | At Loss | 2024-01-05 | At Loss |
| 2024-03-07 | At Loss | 2024-01-04 | At Loss |
| 2024-03-06 | At Loss | 2024-01-03 | At Loss |
| 2024-03-05 | At Loss | 2024-01-02 | At Loss |
| 2024-03-04 | At Loss | 2023-12-29 | At Loss |
| 2024-03-01 | At Loss | 2023-12-28 | At Loss |
| 2024-02-29 | At Loss | 2023-12-27 | At Loss |
| 2024-02-28 | At Loss | 2023-12-22 | At Loss |
| 2024-02-27 | At Loss | 2023-12-21 | At Loss |
| 2024-02-26 | At Loss | 2023-12-20 | At Loss |
| 2024-02-23 | At Loss | 2023-12-19 | At Loss |
| 2024-02-22 | At Loss | 2023-12-18 | At Loss |
| 2024-02-21 | At Loss | 2023-12-15 | At Loss |
| 2024-02-20 | At Loss | 2023-12-14 | At Loss |
| 2024-02-19 | At Loss | 2023-12-13 | At Loss |
| 2024-02-16 | At Loss | 2023-12-12 | At Loss |
| 2024-02-15 | At Loss | 2023-12-11 | At Loss |
| 2024-02-14 | At Loss | 2023-12-08 | At Loss |
| 2024-02-13 | At Loss | 2023-12-07 | At Loss |
| 2024-02-12 | At Loss | 2023-12-06 | At Loss |
Vicore Pharma Holding AB (OSTO:VICO) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Vicore Pharma Holding AB
ISIN : SE0007577895
Compare
Compare
Traded in other countries / regions
VICO.Sweden6Y4.Germany IPO Date
2015-12-10Description
Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers